Weekly Digest
May 11 – May 10, 2026 · 8 stories
The connective tissue this week was vertical integration as a survival strategy. NVIDIA is buying into its own suppliers, Volkswagen is buying deeper into Rivian's software stack, AMETEK is rolling up adjacent instrumentation, and Atrium is absorbing a rival health system outright — each betting that control of the next link in the chain beats arm's-length contracts. Anthropic's revenue surge shows the prize that justifies all this consolidation: whoever owns the full stack, from silicon to customer, captures the margin. Even Washington's new pre-release model testing fits the pattern — it is the government trying to integrate itself into the AI pipeline before the technology outruns oversight.
Anthropic reported its annualized revenue tripled from $9 billion to over $30 billion, putting it ahead of OpenAI's roughly $24 billion run rate for the first time. Roughly 80% of Anthropic's revenue comes from enterprise API and developer contracts, and over 1,000 customers now spend more than $1 million a year on Claude. OpenAI disputes the comparison on accounting grounds, but the trajectory — among the fastest revenue ramps ever recorded — is hard to argue with.
AMETEK struck a definitive all-cash agreement on May 6 to acquire a portfolio of instrumentation businesses from Indicor, LLC for approximately $5 billion. The target generates about $1.1 billion in annual sales with a heavy base of recurring consumables and aftermarket revenue, and will fold into AMETEK's Electronic Instruments and Electromechanical groups. AMETEK will fund it through its credit facility and new debt, with closing expected in the second half of 2026.
Volkswagen's U.S. arm bought 62.9 million new Rivian shares at $15.90 on April 30 — a roughly $1 billion milestone payment that lifted its stake from 8.6% to 15.9% and made it Rivian's largest shareholder for the first time since the 2021 IPO. The purchase was triggered by the companies' software and electrical-architecture joint venture hitting its latest testing milestone. VW has now deployed about $3.3 billion of its $5.8 billion commitment, with the stake potentially climbing past 20% by 2027.
CVS Health blew past Q1 estimates on May 6 and raised its 2026 guidance, with all three segments — insurer Aetna, retail pharmacy, and health services — topping Wall Street. The once-troubled Aetna unit showed clear improvement, echoing a sector-wide payer rebound as UnitedHealth, Humana, Elevance, and Cigna all managed medical costs better than recent quarters. The turnaround came the hard way: aggressive premium hikes, narrowed networks, and exits from unprofitable Medicare Advantage and ACA business.
Charlotte-based Atrium Health announced a proposed combination to become the sole corporate member of the nonprofit that owns WakeMed, pledging a $2 billion capital commitment over a decade and projecting 3,300 new jobs in Wake County. The plan would expand campuses in Raleigh, Cary, and Garner but drew swift pushback from North Carolina officials, delaying a county commissioners' vote. Any deal still needs review by the state attorney general and the FTC.
The Center for AI Standards and Innovation announced agreements with Google DeepMind, Microsoft, and Elon Musk's xAI giving the federal government early access to evaluate their AI models before public launch. It marks a notable shift toward pre-deployment oversight of frontier systems, brokered through voluntary vendor cooperation rather than legislation. The arrangement gives Washington a window into model capabilities it has never had before.
NVIDIA announced agreements with Corning worth $3.2 billion and IREN worth $2.1 billion, deepening its strategy of taking equity-style stakes in its own supply chain. Corning will increase U.S. optical connectivity capacity tenfold and expand fiber production by more than 50%, including three new plants in North Carolina and Texas. The deals are part of an NVIDIA investment push that has topped $40 billion in equity bets across the AI buildout.
The FDA approved Veppanu (vepdegestrant), a heterobifunctional protein degrader, for ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer on May 1 — a validation of the emerging targeted-degrader class. Days later, on May 8, the agency expanded the label for argenx's Vyvgart and Vyvgart Hytrulo to cover all serotypes of adult generalized myasthenia gravis. Both decisions widen access in hard-to-treat patient populations.